NAD+ Boosters Reshape the Gut Microbiome, Too. Nestlé Reports in Nature Metabolism
WELLNESS

NAD+ Boosters Reshape the Gut Microbiome, Too. Nestlé Reports in Nature Metabolism

By Hana · · https://www.nutraingredients.com/Article/2026/03/05/nad-boosters-may-also-boost-gut-microbes-and-beneficial-metabolites/
KO | EN

A randomized controlled trial led by Nestlé Research, Nestlé Health Science, and Cryptobiotix scientists, published in Nature Metabolism volume 8 (pages 62-73) in 2026, sharpens the mechanism understanding of the NAD+ booster category. The headline carries two messages. NMN and NR both double NAD+, and they do so alongside metabolic adaptation in the gut microbiome that increases short-chain fatty acid (SCFA) production.

65 adults, 14 days, four arms

The trial was randomized, open-label, and placebo-controlled with four arms. Sixty-five healthy adults, mean age 35, received one of four 14-day regimens. Nicotinamide (Nam) 500 mg/day, NR 1,000 mg/day, NMN 1,000 mg/day, or placebo.

Results were consistent. Both NR and NMN approximately doubled whole-blood NAD+ levels. Nam produced only short-term changes. On these data alone, the “NMN vs NR, which is better” debate clarifies. The two are clinically equivalent.

The microbiome enters the picture

The interesting part lies elsewhere. NR and NMN do not simply raise NAD+ by direct conversion. They are accompanied by metabolic adaptation in the gut microbiome. Both supplements increased SCFA production, and gut bacteria converted them to nicotinic acid (niacin).

The mechanism implication is direct. Beyond direct gastrointestinal absorption converting NMN/NR into circulating NAD+, an indirect pathway operates simultaneously. Gut bacteria transform these compounds, and the resulting nicotinic acid raises NAD+ via the Preiss-Handler pathway. The model is no longer simple vitamin supplementation. It is a three-way interaction between supplement, microbiome, and host metabolism.

Nam showed a different pattern. It produced only short-term NAD+ changes without microbiome adaptation. Despite belonging to the same vitamin B3 family, the difference emerges at the gut bacterial conversion stage.

The Preiss-Handler pathway gets new attention

NAD+ synthesis runs through several pathways. De novo synthesis (from tryptophan), the salvage pathway (NAM through NMN to NAD+), and the Preiss-Handler pathway (from nicotinic acid). The key finding here is that NR and NMN, after gut bacterial conversion to nicotinic acid, raise NAD+ through the Preiss-Handler pathway.

This finding refines the simplistic model of “NMN is absorbed and used directly” in the anti-aging category. Multiple layers operate simultaneously, including absorption, conversion, and microbiome adaptation.

Convergence of gut health and anti-aging

The biggest industry message is category convergence. NAD+ boosters started in the anti-aging category, but this data suggests they also belong in the gut health category. Increased SCFA production ties directly to standard gut health effects: gut barrier protection, inflammation regulation, insulin sensitivity improvement.

When choosing NAD+ supplements, consumers move from a single-category message of “turning back the aging clock” to a multi-layered message of “anti-aging plus gut health plus microbiome adaptation.” The same direction as dsm-firmenich and Symrise’s plant exosome announcements and Olay’s cell adhesion finding the same quarter. Mechanism targets narrow while action categories expand.

What changes in daily choice

The mechanism precision shapes consumer choices in concrete ways.

Selection: The data strengthens the position that NMN and NR are clinically equivalent. Choose by price, absorption stability, or formulation. The marketing claim “NMN costs more so it must be better” is not supported by clinical data.

Dose: 1,000 mg/day is the dose that produced the 2x NAD+ increase in trials. Many over-the-counter supplements use 250-500 mg/day, lower than the verified clinical dose. Expecting comparable effects at lower doses is reasonable to question.

Combination: Gut health care and NAD+ supplements are not separate categories. Fiber, fermented foods, and prebiotic inputs likely influence the effect size of NAD+ supplements. Managing both categories together is appropriate.

Duration: While 14 days produced 2x NAD+, microbiome adaptation may take longer to stabilize. 4-8 weeks is a common evaluation window.

Same-quarter NAD+ category direction

This announcement aligns with other NAD+ data the same quarter. February 2026’s NMN meta-analysis reported -2.15 mmHg in diastolic blood pressure. PQQ + NMN exercise trials and NMN skeletal muscle anti-inflammatory trials appeared in the same window. From single anti-aging effect to blood pressure, exercise capacity, anti-inflammatory, and microbiome, the effect domain is widening.

The NAD+ booster category is at the inflection point from a single market to a multi-layered market. This Nestlé announcement is one face of that subdivision.